Picture Stier Group MIXiii Lifescience Healthtech Conference 650x100px

Document › Details

Creoptix AG. (9/5/18). "Press Release: Creoptix Attracts Waters as Corporate Investor". Wädenswil (Zurich).

	Organisation	Creoptix AG
	Group	Spectris (Group)
	Organisation 2	Waters Corporation (NYSE: WAT)
	Group	Waters (Group)
	Product	WAVEsystem (Creoptix)
	Product 2	waveguide interferometry technology
	Index term	Creoptix–Waters: investment, 201809 investment by new investor Waters Corp
	Person	Gerhardt, Geoff (Scitara 202103 CTO before Waters 201809 Senior Director Corporate Development)
	Person 2	Végh, Mátyás (Creoptix 201210–201912 Managing Partner before Genetics Company LEFT 1/20)

Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today announced it secured new investment in the company from Waters Corporation (NYSE: WAT). Additionally, Geoff Gerhardt, Ph.D., Sr. Director, Corporate Development at Waters will join Creoptix board of directors effective immediately.

Creoptix developed and markets Creoptix WAVE systems to study molecular interactions in realtime. Based on proprietary waveguide technology and no-clog microfluidics, WAVE systems uniquely combine unparalleled resolution and crude sample robustness to generate unmatched data quality. The technology is facilitating new analytical applications that were not previously possible, such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker and biotherapeutics development.

“We are very proud to be partnering with Waters Corporation as corporate investor, including participation on our board of directors,” said Matyas Vegh, CEO of Creoptix. “This not only bolsters our analytical science expertise and resources to expand our presence in the market, but it also acknowledges our technology and its potential.”

” New innovative analytical technologies are critical to accelerating biopharmaceutical therapeutic drug development processes. Creoptix has developed unique technology that enables protein researchers to generate higher quality protein binding data with significantly improved robustness compared to legacy technologies. Waters is excited to support Creoptix's vision for widespread adoption of its WAVE System technology,” said Dr. Gerhardt.

About Creoptix (www.creoptix.com)

Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and offices near Boston, USA. Creoptix focuses on next generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, their Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and in even crude samples like undiluted serum or plasma.

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 27 countries, including 11 manufacturing facilities, and with products available in more than 100 countries.

Record changed: 2023-06-05